Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Understanding the way in which drugs are metabolized by cytochrome P450 2D6 (CYP2D6) and hence the underlying mechanisms that define potential toxicity is crucial to avoid adverse reactions. The high occurrence of CYP2D6 polymorphs enhances the complexity of the toxicity assessment of a drug candidate and should be tackled from early drug discovery phase on. The recent increase in available mammalian CYP2D6 X-ray structures opens the gateway to the development of in silico three-dimensional CYP2D6 toxicity prediction techniques that address also the major clinically relevant allelic variants. This review presents the basic principles needed for comprehending the enzyme particularities, gives a concise overview of several clinical relevant allelic CYP2D6 variants, and explores the state-of-the-art CYP2D6 research field to accelerate the development and use of such integrative in silico modeling technologies. This article is categorized under: Structure and Mechanism > Computational Biochemistry and Biophysics Structure and Mechanism > Molecular Structures Software > Molecular Modeling K E Y W O R D S adverse effects, CYP2D6, cytochrome P450, polymorphism, rational drug design, toxicity 1 | INTRODUCTION 1.1 | Cytochrome P450 2D6 metabolic relevance in drug discoveryEarly toxicity evaluation is of great importance to improve the worrying drug attrition rates. In the last two decades, tighter drug safety regulations steered the pharmaceutical industry to invest more time and resources in reduction of drug failures due to toxicity in early drug development (Waring et al., 2015). Accurate prediction of the toxicity profile of a potential drug candidate is a multifaceted challenge, especially since in essence all molecules are toxic to some degree for living organisms. To define the border between toxic and nontoxic, both the pharmacokinetics and the pharmacodynamics of the drug need to be assessed. Absorption, distribution, metabolism, and excretion processes strongly impact the bioavailability and hence the extent of drug toxicity in the body. Xenobiotic metabolism is a critical process in drug clearance and avoiding any potential metabolic liability is one of the major endpoints addressed in assessment studies during the early phase clinical trials. Drugs administered orally can either be readily excreted or undergo a metabolic biotransformation by chemical modification of the compound into a more soluble product facilitating the renal excretion. The generally known four types of hepatic reactions during the biotransformation are categorized into phase I (oxidation, hydrolysis, and reduction) and phase II (conjugation). Phase I reactions are dominated by the cytochrome enzyme P450 superfamily (abbreviated P450 henceforth). Cytochrome
Understanding the way in which drugs are metabolized by cytochrome P450 2D6 (CYP2D6) and hence the underlying mechanisms that define potential toxicity is crucial to avoid adverse reactions. The high occurrence of CYP2D6 polymorphs enhances the complexity of the toxicity assessment of a drug candidate and should be tackled from early drug discovery phase on. The recent increase in available mammalian CYP2D6 X-ray structures opens the gateway to the development of in silico three-dimensional CYP2D6 toxicity prediction techniques that address also the major clinically relevant allelic variants. This review presents the basic principles needed for comprehending the enzyme particularities, gives a concise overview of several clinical relevant allelic CYP2D6 variants, and explores the state-of-the-art CYP2D6 research field to accelerate the development and use of such integrative in silico modeling technologies. This article is categorized under: Structure and Mechanism > Computational Biochemistry and Biophysics Structure and Mechanism > Molecular Structures Software > Molecular Modeling K E Y W O R D S adverse effects, CYP2D6, cytochrome P450, polymorphism, rational drug design, toxicity 1 | INTRODUCTION 1.1 | Cytochrome P450 2D6 metabolic relevance in drug discoveryEarly toxicity evaluation is of great importance to improve the worrying drug attrition rates. In the last two decades, tighter drug safety regulations steered the pharmaceutical industry to invest more time and resources in reduction of drug failures due to toxicity in early drug development (Waring et al., 2015). Accurate prediction of the toxicity profile of a potential drug candidate is a multifaceted challenge, especially since in essence all molecules are toxic to some degree for living organisms. To define the border between toxic and nontoxic, both the pharmacokinetics and the pharmacodynamics of the drug need to be assessed. Absorption, distribution, metabolism, and excretion processes strongly impact the bioavailability and hence the extent of drug toxicity in the body. Xenobiotic metabolism is a critical process in drug clearance and avoiding any potential metabolic liability is one of the major endpoints addressed in assessment studies during the early phase clinical trials. Drugs administered orally can either be readily excreted or undergo a metabolic biotransformation by chemical modification of the compound into a more soluble product facilitating the renal excretion. The generally known four types of hepatic reactions during the biotransformation are categorized into phase I (oxidation, hydrolysis, and reduction) and phase II (conjugation). Phase I reactions are dominated by the cytochrome enzyme P450 superfamily (abbreviated P450 henceforth). Cytochrome
Methadone is a morphine-substitute drug in methadone maintenance treatment (MMT) program to treat patients with opioid dependency. However, the methadone clinical effects are depending on the methadone metabolism rates that vary among the patients with genetic polymorphism of cytochrome P450s (CYPs). Our previous study showed methadone has different binding affinity due to the polymorphisms in CYP2B6, CYP2D6 and CYP3A4 that could contribute to the methadone metabolism rate. In this work, the conformation and interactions of R- and S-methadone in wild type CYP2B6, CYP2D6 and CYP3A4 were further studied in order to understand behaviour of R- and S-methadone at the CYP binding site. Clustering analysis showed that the conformation of R- and S-methadone in CYP2B6 are most stable, thus could lead to a higher efficiency of methadone metabolism. The conformation fluctuation of methadone in CYP2D6 could due to relatively smaller binding pocket compared with CYP2B6 and CYP3A4. The binding sites volumes of the studied CYPs were also found to be increased upon the binding with methadone. Therefore, this might contributed to the interactions of both R- and S-methadone in CYPs were mainly by hydrophobic contacts, van der Waals and electrostatic interactions. In the future, should an inhibitor for CYP is to be designed to prolong the prolonged opioid effect, the inhibitor should cater for single CYP isozyme as this study observed the behavioural differences of methadone in CYP isozymes. Graphical Abstract:
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.